Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2013

01.10.2013 | Original Article

Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy

verfasst von: Takahide Taguchi, Goshi Nishimura, Masahiro Takahashi, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Yasuhiro Arai, Yukiko Yamashita, Osamu Shiono, Mariko Hirama, Yasunori Sakuma, Jun-ichi Ishitoya, Masaharu Hata, Ichiro Ogino, Nobuhiko Oridate

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

To review our experience with concurrent chemoradiotherapy (CCRT) for patients with advanced resectable squamous cell carcinoma (SCC) of the larynx and to evaluate the factors affecting survival and larynx preservation.

Study design

Retrospective study.

Subjects and methods

The records of 102 patients with stage III or IV resectable SCC of the larynx treated with CCRT between February 1994 and March 2009 were reviewed. Of 102 patients, 59 were treated with high-dose regimens, including cisplatin, 5-fluorouracil (5-FU), methotrexate, and leucovorin or docetaxel, cisplatin, and 5-FU, and 43 were treated with low-dose regimens, including carboplatin and uracil-tegafur or S-1. Radiotherapy was delivered 5 days a week using a single daily fraction of 1.8–2.0 Gray (Gy), to a total dose of 66.0–70.2 Gy. Overall survival (OS), disease-specific survival (DSS), and DSS with larynx preservation were estimated using Kaplan–Meier methods. The log-rank test and Cox proportional hazards regression were used to identify significant prognostic factors for DSS and DSS with larynx preservation.

Results

The 5-year OS and DSS for all patients treated with CCRT were 63.9 and 70.7 %, respectively. The 5-year DSS with larynx preservation was 54.1 %. On multivariate analysis, N stage, synchronous multiple primary cancers, and the contents of chemotherapy were significant predictors of OS for patients undergoing CCRT; T stage, N stage, and the contents of chemotherapy were significant prognostic factors for larynx preservation.

Conclusion

The treatment method including the indication for CCRT may be determined by the contents of the chemotherapy and the T and N stages of laryngeal SCC. It is important to diagnose multiple synchronous primary cancers before CCRT.
Literatur
1.
Zurück zum Zitat Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer (1991) The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324(24):1685–1690 Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer (1991) The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324(24):1685–1690
2.
Zurück zum Zitat Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091–2098PubMedCrossRef Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091–2098PubMedCrossRef
3.
Zurück zum Zitat Katori H, Tsukuda M, Mochimatu I et al (2004) Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 90(2):348–352PubMedCrossRef Katori H, Tsukuda M, Mochimatu I et al (2004) Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 90(2):348–352PubMedCrossRef
4.
Zurück zum Zitat Taguchi T, Tsukuda M, Mikami Y et al (2006) Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx. Acta Otolaryngol 126(4):408–413PubMedCrossRef Taguchi T, Tsukuda M, Mikami Y et al (2006) Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx. Acta Otolaryngol 126(4):408–413PubMedCrossRef
5.
Zurück zum Zitat Taguchi T, Ikeda Y, Mikami Y et al (2003) Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma. Anticancer Res 23(1B):713–717PubMed Taguchi T, Ikeda Y, Mikami Y et al (2003) Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma. Anticancer Res 23(1B):713–717PubMed
6.
Zurück zum Zitat Tsukuda M, Ishitoya J, Mikami Y et al (2009) Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 64(5):945–952PubMedCrossRef Tsukuda M, Ishitoya J, Mikami Y et al (2009) Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 64(5):945–952PubMedCrossRef
7.
Zurück zum Zitat Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355(9208):949–955PubMed Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355(9208):949–955PubMed
8.
Zurück zum Zitat Seiwert TY, Cohen EE (2005) State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92(8):1341–1348PubMedCrossRef Seiwert TY, Cohen EE (2005) State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92(8):1341–1348PubMedCrossRef
9.
Zurück zum Zitat Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852PubMedCrossRef Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852PubMedCrossRef
10.
Zurück zum Zitat Jeremic B, Milicic B (2009) Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol 32(2):163–168PubMedCrossRef Jeremic B, Milicic B (2009) Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol 32(2):163–168PubMedCrossRef
11.
Zurück zum Zitat Lodder WL, Pameijer FA, Rasch CR, van den Brekel MW, Balm AJ (2012) Prognostic significance of radiologically determined neck node volume in head and neck cancer: a systematic review. Oral Oncol 48(4):298–302PubMedCrossRef Lodder WL, Pameijer FA, Rasch CR, van den Brekel MW, Balm AJ (2012) Prognostic significance of radiologically determined neck node volume in head and neck cancer: a systematic review. Oral Oncol 48(4):298–302PubMedCrossRef
12.
Zurück zum Zitat Jakobsen J, Hansen O, Jorgensen KE, Bastholt L (1998) Lymph node metastases from laryngeal and pharyngeal carcinomas–calculation of burden of metastasis and its impact on prognosis. Acta Oncol 37(5):489–493PubMedCrossRef Jakobsen J, Hansen O, Jorgensen KE, Bastholt L (1998) Lymph node metastases from laryngeal and pharyngeal carcinomas–calculation of burden of metastasis and its impact on prognosis. Acta Oncol 37(5):489–493PubMedCrossRef
13.
Zurück zum Zitat Suntharalingam M, Haas ML, Van Echo DA et al (2001) Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 91(3):548–554PubMedCrossRef Suntharalingam M, Haas ML, Van Echo DA et al (2001) Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 91(3):548–554PubMedCrossRef
14.
Zurück zum Zitat Douple EB, Richmond RC, O’Hara JA, Coughlin CT (1985) Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 12(suppl A):111–124PubMedCrossRef Douple EB, Richmond RC, O’Hara JA, Coughlin CT (1985) Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 12(suppl A):111–124PubMedCrossRef
15.
Zurück zum Zitat Colevas AD, Posner MR (1998) Docetaxel in head and neck cancer: a review. Am J Clin Oncol 21(5):482–486PubMedCrossRef Colevas AD, Posner MR (1998) Docetaxel in head and neck cancer: a review. Am J Clin Oncol 21(5):482–486PubMedCrossRef
16.
Zurück zum Zitat Fu KK, Phillips TL (1991) Biologic rationale of combined radiotherapy and chemotherapy. In: Hematol Oncol Clin North Am :737–751 Fu KK, Phillips TL (1991) Biologic rationale of combined radiotherapy and chemotherapy. In: Hematol Oncol Clin North Am :737–751
17.
Zurück zum Zitat Smalley SR, Kimler BF, Evans RG (1991) 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 20(2):207–211PubMedCrossRef Smalley SR, Kimler BF, Evans RG (1991) 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 20(2):207–211PubMedCrossRef
18.
Zurück zum Zitat Esposito ED, Bevilacqua L, Guadagno MT (2000) Multiple primary malignant neoplasm in patients with laryngeal carcinoma. J Surg Oncol 74(1):83–86PubMedCrossRef Esposito ED, Bevilacqua L, Guadagno MT (2000) Multiple primary malignant neoplasm in patients with laryngeal carcinoma. J Surg Oncol 74(1):83–86PubMedCrossRef
19.
Zurück zum Zitat Nikolaou AC, Markou CD, Petridis DG, Daniilidis IC (2000) Second primary neoplasms in patients with laryngeal carcinoma. Laryngoscope 110(1):58–64PubMedCrossRef Nikolaou AC, Markou CD, Petridis DG, Daniilidis IC (2000) Second primary neoplasms in patients with laryngeal carcinoma. Laryngoscope 110(1):58–64PubMedCrossRef
20.
Zurück zum Zitat Yabuki K, Kubota A, Horiuchi C, Taguchi T, Nishimura G, Inamori M (2013) Limitations of PET and PET/CT in detecting upper gastrointestinal synchronous cancer in patients with head and neck carcinoma. Eur Arch Otorhinolaryngol 270(2):727–733PubMedCrossRef Yabuki K, Kubota A, Horiuchi C, Taguchi T, Nishimura G, Inamori M (2013) Limitations of PET and PET/CT in detecting upper gastrointestinal synchronous cancer in patients with head and neck carcinoma. Eur Arch Otorhinolaryngol 270(2):727–733PubMedCrossRef
21.
Zurück zum Zitat Ikeda Y, Tsukuda M, Ishitoya J et al (2005) Four cases of simultaneous triple primary cancers of the hypopharynx, esophagus, and stomach. Otolaryngol Head Neck Surg 132(5):788–793PubMedCrossRef Ikeda Y, Tsukuda M, Ishitoya J et al (2005) Four cases of simultaneous triple primary cancers of the hypopharynx, esophagus, and stomach. Otolaryngol Head Neck Surg 132(5):788–793PubMedCrossRef
22.
Zurück zum Zitat Brockstein B, Haraf DJ, Rademaker AW et al (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15(8):1179–1186PubMedCrossRef Brockstein B, Haraf DJ, Rademaker AW et al (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15(8):1179–1186PubMedCrossRef
23.
Zurück zum Zitat Knegjens JL, Hauptmann M, Pameijer FA et al (2011) Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck 33(3):375–382PubMed Knegjens JL, Hauptmann M, Pameijer FA et al (2011) Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck 33(3):375–382PubMed
24.
Zurück zum Zitat Stenson KM, Maccracken E, Kunnavakkam R et al (2012) Chemoradiation for patients with large-volume laryngeal cancers. Head Neck 34(8):1162–1167PubMedCrossRef Stenson KM, Maccracken E, Kunnavakkam R et al (2012) Chemoradiation for patients with large-volume laryngeal cancers. Head Neck 34(8):1162–1167PubMedCrossRef
25.
Zurück zum Zitat Knab BR, Salama JK, Solanki A et al (2008) Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol 19(9):1650–1654PubMedCrossRef Knab BR, Salama JK, Solanki A et al (2008) Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol 19(9):1650–1654PubMedCrossRef
Metadaten
Titel
Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy
verfasst von
Takahide Taguchi
Goshi Nishimura
Masahiro Takahashi
Masanori Komatsu
Daisuke Sano
Naoko Sakuma
Yasuhiro Arai
Yukiko Yamashita
Osamu Shiono
Mariko Hirama
Yasunori Sakuma
Jun-ichi Ishitoya
Masaharu Hata
Ichiro Ogino
Nobuhiko Oridate
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2013
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-013-2261-3

Weitere Artikel der Ausgabe 4/2013

Cancer Chemotherapy and Pharmacology 4/2013 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.